Evidence map›Paper›PMID 27100373›Full record

ArticleDrug testing and analysis2017

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Simon D Brandt, Pierce V Kavanagh, Geraldine Dowling, Brian Talbot, Folker Westphal, Markus R Meyer, Hans H Maurer, Adam L Halberstadt

Abstract read
In one paragraph

Article in Drug testing and analysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Toxicology and Analysis of Psychoactive Tryptamines.International journal of molecular sciences · 2020
    Review
  5. Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
Pierce V KavanaghDepartment of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.
Geraldine DowlingDepartment of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.
Brian TalbotSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Folker WestphalState Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, D-24116, Kiel, Germany.
Markus R MeyerDepartment of Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, D-69120, Heidelberg, Germany.
Hans H MaurerDepartment of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, D-66421, Homburg (Saar), Germany.
Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, La Jolla, CA, 92093-0804, USA.

Funding

MONOAMINES &HALLUCINOGENS'EFFECTS ON RAT BEHAVIORR01DA002925 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A · 1985 to 2015
$4.2M
Role of the prefrontal cortex in serotonergic modulation of interval timingK01MH100644 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2014 to 2016
$466k
NIDA NIH HHS R01 DA002925NIMH NIH HHS K01 MH100644
6 · The paper itself

Abstract

Many N,N-dialkylated tryptamines show psychoactive properties in humans and the number of derivatives involved in multidisciplinary areas of research has grown over the last few decades. Whereas some derivatives form the basis of a range of medicinal products, others are predominantly encountered as recreational drugs, and in some cases, the areas of therapeutic and recreational use can overlap. In recent years, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) has appeared as a new psychoactive substance (NPS) and 'research chemical' whereas 4-acetoxy-DALT and the ring-unsubstituted DALT have only been detected very recently. Strategies pursued in the authors' laboratories included the preparation and biological evaluation of previously unreported N,N-diallyltryptamines (DALTs). This report describes the analytical characterization of 17 DALTs. Fifteen DALTs were prepared by a microwave-accelerated Speeter and Anthony procedure following established procedures developed previously in the authors' laboratories. In addition to DALT, the substances included in this study were 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 4,5-ethylenedioxy-, 5-methyl-, 5-methoxy-, 5-methoxy-2-methyl-, 5-ethoxy-, 5-fluoro-, 5-fluoro-2-methyl-, 5-chloro-, 5-bromo-, 5,6-methylenedioxy-, 6-fluoro-, 7-methyl, and 7-ethyl-DALT, respectively. The DALTs were characterized by nuclear magnetic resonance spectroscopy (NMR), gas chromatography (GC) quadrupole and ion trap (EI/CI) mass spectrometry (MS), low and high mass accuracy MS/MS, photodiode array detection, and GC solid-state infrared analysis, respectively. A comprehensive collection of spectral data was obtained that are provided to research communities who face the challenge of encountering newly emerging substances where analytical data are not available. These data are also relevant to researchers who might wish to explore the clinical and non-clinical uses of these substances. Copyright © 2016 John Wiley & Sons, Ltd.

Indexed as

Allyl CompoundsChromatography, GasHallucinogensIllicit DrugsMagnetic Resonance SpectroscopyMass SpectrometryPsychotropic DrugsTryptaminesAllyl CompoundsHallucinogensIllicit DrugsN,N-diallyl-5-methoxytryptaminePsychotropic DrugsTryptamineschemistryDALTforensicnew psychoactive substancestryptamines

Identifiers

PMID27100373
PMCPMC5412731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.